WCM
CTKB icon

WealthTrak Capital Management’s Cytek Biosciences CTKB Stock Holding History

WealthTrak Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35
Closed -$141 – 971
2025
Q1 		$141 Buy
+35
New +$181 ﹤0.01% 901

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

WealthTrak Capital Management's CTKB Position: Q2 2025 in Review

WealthTrak Capital Management sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 35 shares — an estimated $141 sold.

WealthTrak Capital Management first reported a position in CTKB in Q1 2025 and held it in 1 quarter. The position peaked at $141 in Q1 2025. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

  • WealthTrak Capital Management reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
  • WealthTrak Capital Management sold 35 Cytek Biosciences shares in Q2 2025, an estimated $141.
  • WealthTrak Capital Management first reported a position in Cytek Biosciences in Q1 2025 and held it in 1 quarter.
  • WealthTrak Capital Management's Cytek Biosciences position peaked at $141 in Q1 2025.
  • 158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on WealthTrak Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.